. 2017 Mar 30;22(4):553. doi: 10.3390/molecules22040553

Table 8.

Pharmacokinetic parameters of GE phenolics with and without ketoconazole co-administration and subsequent treatment of plasma samples with β-glucuronidase.

Compound	Treatment	T_max (min)	C_max (ng/mL)	AUC_last (ng·h/mL)	AUC_last ^a Ratio
6G	−βgd	120	27.18	37.71	-
	+βgd	30	12,473	13,621	361
	+KTZ −βgd	30	256.7	300.2	8
	+KTZ +βgd	30	10,061	18,782	498, 63 ^b
8G	−βgd	NR ^C	0.00	0.00	-
	+βgd	30	948.2	697.6	698
	+KTZ −βgd	30	45.68	59.10	59
	+KTZ +βgd	30	1071	1330	1330, 23 ^b
10G	−βgd	30	55.95	61.80	-
	+βgd	30	740.2	634.7	10
	+KTZ −βgd	30	79.00	174.4	3
	+KTZ +βgd	30	1755	1952	32, 11 ^b
6S	−βgd	10	3.880	1.924	-
	+βgd	5	143.0	126.5	66
	+KTZ −βgd	60	12.44	15.08	8
	+KTZ +βgd	30	228.6	212.5	110, 14 ^b

−βgd: plasma samples without β-glucuronidase treatment; +βgd: plasma samples treated with β-glucuronidase; +KTZ −βgd: ketoconazole co-administered group plasma samples without β-glucuronidase treatment; +KTZ +βgd: ketoconazole co-administered group plasma samples treated with β-glucuronidase; data presented up to 4 significant digits for C_max and AUC_last; ^a AUC_last ratio calculated considering GE group untreated with βgd as reference; ^b AUC_last ratio calculated considering GE group co-administered with KTZ untreated with βgd as reference; ^c NR: not reportable, C_max: peak plasma concentration; AUC_last: Area under the curve; n = 3 per time point; mean values reported.